Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
clinical trials
life sciences
national
4
×
national blog main
europe blog main
brexit
drugs
europe
falsified medicines
fda
innovation
labeling
mhra
national top stories
raleigh-durham blog main
raleigh-durham top stories
regulations
san francisco blog main
san francisco top stories
uk
abbvie
akouos
allergan
alnylam pharmaceuticals
amag pharmaceuticals
amunix
anirvan ghosh
aspire capital fund
astrazeneca
auris health
biogen
bluerock therapeutics
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cerovene
covid-19
What
plans
4
×
end
medicines
brexit
charting
choppy
course
dynamic
period
post
regulation
regulatory
reveals
transition
uk
acquisitions
announced
bio
cash
ceo
clearance
collabs
company
covid
crunch
daniel
deal
didn’t
fda
gilead
gilead’s
goal
help
introduce
ipo
medical
medical’s
meet
month
needs
Language
unset
Current search:
plans
×
biotech
×
national
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
